
Medtech company Coloplast is expecting to reach the same organic growth it landed on in the financial year that just ended for the next financial year of 2021/2022, it states in its year-end report from 2020/2021, which was released on Monday.
Coloplast is now estimating an organic growth of 7 percent in current exhange rates (CER) for the new financial year, after the organic growth in 2020/2021 likewise ended on 7 percent.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app